Flumazenil
This medication acts as a reversal agent for benzodiazepine sedatives by competing with them at the same receptor sites in the brain, rapidly restoring consciousness and breathing. It is used in emergency settings to reverse excessive sedation or overdose from benzodiazepine medications.
Molecular Weight
303.2900 g/mol
LogP
1.00
TPSA
64.40 Ų
Lipinski RO5
Pass
Therapeutic Areas
Mechanism of Action
Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, …
2D Structure
Cite this structure
Embed this structure
SMILES
CCOC(=O)c1ncn2c1CN(C)C(=O)c1cc(F)ccc1-2
InChI
InChI=1S/C15H14FN3O3/c1-3-22-15(21)13-12-7-18(2)14(20)10-6-9(16)4-5-11(10)19(12)8-17-13/h4-6,8H,3,7H2,1-2H3
Molecular Formula
C15H14FN3O3
HBD / HBA
- / 5
Rotatable Bonds
3
Heavy Atoms
22
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
This medication acts as a reversal agent for benzodiazepine sedatives by competing with them at the same receptor sites in the brain, rapidly restoring consciousness and breathing. It is used in emergency settings to reverse excessive sedation or overdose from benzodiazepine medications.
Enhances the effect of gamma-aminobutyric acid (GABA) at GABA-A receptors by binding to an allosteric site and increasing the frequency of chloride ion channel opening. This produces anxiolytic, sedative, hypnotic, and anticonvulsant effects.
Yes, Flumazenil is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL407. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 3373. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="flumazenil"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/flumazenil/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/flumazenil/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/flumazenil/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="flumazenil"></drugfyi-drug>